Relmada Therapeutics, Inc.
RLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.01 | -0.01 |
| FCF Yield | -329.96% | -166.63% | -401.53% | -116.06% |
| EV / EBITDA | -0.15 | 5.48 | -0.13 | -0.28 |
| Quality | ||||
| ROIC | -236.14% | -121.49% | -114.82% | -60.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.65 | 0.52 | 0.66 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -0.19% | 50.23% | -12.98% | -230.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | -0.83 | 0.03 | 0.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -3,247,427.05 |